Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brainstorm Cell Therapeutics

0.8600
-0.0160-1.83%
Post-market: 0.87000.0100+1.16%18:56 EDT
Volume:85.32K
Turnover:75.25K
Market Cap:5.61M
PE:-0.37
High:0.9140
Open:0.9140
Low:0.8500
Close:0.8760
Loading ...

Company Profile

Company Name:
Brainstorm Cell Therapeutics
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
27
Office Location:
1325 Avenue of Americas,28th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Directors

Name
Position
Irit Arbel
Vice-Chairperson and Director
Jacob Frenkel
Chairperson and Director
Uri Yablonka
Director, EVP, Chief Business Officer and Secretary
Anthony Polverino
Director
Menghisteab Bairu
Director
Nir Naor
Director

Shareholders

Name
Position
Chaim Lebovits
Chief Executive Officer
Stacy Lindborg
Co-Chief Executive Officer
Alla Patlis
Interim Chief Financial Officer and Controller
Uri Yablonka
Director, EVP, Chief Business Officer and Secretary